Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Share-based Compensation (2024 - 2025)

Xilio Therapeutics' Share-based Compensation history spans 2 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 28.65% year-over-year to $1.1 million; the TTM value through Sep 2025 reached -$809000.0, changed N/A, while the annual FY2024 figure was $100000.0, 98.65% down from the prior year.
  • Share-based Compensation for Q3 2025 was $1.1 million at Xilio Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.8 million in Q1 2024 and bottomed at -$4.8 million in Q4 2024.